中国肿瘤生物治疗杂志2026，Vol.33Issue(2)：155-162,8.DOI:10.3872/j.issn.1007-385x.2026.02.006
安罗替尼联合ICI一线治疗晚期肺鳞状细胞癌的疗效和安全性:37例单中心回顾性队列分析
Efficacy and safety of anlotinib combined with ICI as first-line treatment for advanced lung squamous cell carcinoma:a single-center retrospective cohort study of 37 patients
林勇 1肖春妹 2谢强 2陈群 2石琴 2罗杨 2胡颖 2林恒2
作者信息
- 1. 福建省福州肺科医院胸外科,福建 福州 350008
- 2. 福建省福州肺科医院 肿瘤科,福建 福州 350008
- 折叠
摘要
Abstract
Objective:To explore the efficacy and safety of anlotinib combined with immune checkpoint inhibitors(ICI)as first-line treatment for advanced lung squamous cell carcinoma(LUSC).Methods:In this single-center retrospective cohort study,37 consecutive treatment-naïve advanced LUSC patients treated at Fuzhou Pulmonary Hospital of Fujian between October 2018 and December 2023 were enrolled.All patients received anlotinib(8,10,or 12 mg/d;administered for 2 weeks followed by 1 week off)combined with PD-1/PD-L1 inhibitors.The primary endpoint was progression-free survival(PFS),and the secondary endpoints included objective response rate(ORR),disease control rate(DCR),and treatment-related adverse event(TRAE).Results:With a median follow-up of 15.2 months,the ORR reached 54.1％(20/37),the DCR was 97.3％(36/37),the median PFS was 11.8 months(95％CI:8.3-NA),and the 12-month PFS rate was 48.6％.Exploratory subgroup analyses showed that that patients receiving anlotinib at 12 mg demonstrated significantly longer median PFS(not reached vs 7.5 months;HR=0.09,95％CI:0.01-0.67;P＜0.01)and a higher ORR(100％vs 42.9％,P＜0.01)compared to those receiving 8 or 10 mg.Stage-stratified analysis showed that the ORR of patients in stage ⅢB/ⅢC disease was significantly better than those in stage Ⅳ(84.6％vs 41.7％,P=0.02).In terms of safety,62.2％(23/37)of the patients developed TRAE,mainly grade 1-2 hypertension(29.7％[11/37])and hand-foot syndrome(21.6％[8/37]).Three patients(8.1％)discontinued treatment due to grade 3 TRAE.Conclusion:Anlotinib combined with ICI as a first-line treatment regimen for advanced LUSC demonstrates promising therapeutic efficacy and manageable safety profiles.Notably,in exploratory analyses,the 12 mg dose group exhibited potential signals of superior efficacy,and patients with earlier-stage disease showed a higher ORR.These findings warrant further validation through large-scale prospective studies.关键词
肺鳞状细胞癌/安罗替尼/免疫检查点抑制剂/免疫治疗/联合治疗/治疗相关不良事件Key words
lung squamous cell carcinoma(LUSC)/anlotinib/immune checkpoint inhibitor(ICI)/immunotherapy/combination therapy/treatment-related adverse event(TRAE)分类
医药卫生引用本文复制引用
林勇,肖春妹,谢强,陈群,石琴,罗杨,胡颖,林恒..安罗替尼联合ICI一线治疗晚期肺鳞状细胞癌的疗效和安全性:37例单中心回顾性队列分析[J].中国肿瘤生物治疗杂志,2026,33(2):155-162,8.
